Peptide Comparison
GHRP-6 vs CJC-1295 + Ipamorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
GHRP-6 and CJC-1295 + Ipamorelin share the ghrp / gh-secretagogue classes and carry roughly equivalent evidence (Anecdotal + Animal Studies / Anecdotal + Animal Studies). On the catalogued data layer GHRP-6 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; GHRP-6's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| GHRP-6 | CJC-1295 + Ipamorelin | |
|---|---|---|
| Class | GHRP; ghrelin receptor agonist | GHRH analog + selective GHRP blend (GH-secretagogue stack) |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist with strong orexigenic effect | Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). |
| Route | SC / Intranasal | SC injection |
| Half-life | ~15-30 min | CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs |
| Dosage (research) | 100-300 mcg SC 2-3x daily | 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off |
| Evidence tier | Anecdotal + Animal Studies | Anecdotal + Animal Studies |
| Research depth | 163 indexed | 5 indexed |
| Availability | Research Chemical | Compounding Restricted |
| Reported risks | Strong hunger; cortisol/prolactin rise; water retention | Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHRP-6 or CJC-1295 + Ipamorelin?
GHRP-6 and CJC-1295 + Ipamorelin share the ghrp / gh-secretagogue classes and carry roughly equivalent evidence (Anecdotal + Animal Studies / Anecdotal + Animal Studies). On the catalogued data layer GHRP-6 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; GHRP-6's evidence base is currently denser.
What is the difference between GHRP-6 and CJC-1295 + Ipamorelin?
GHRP-6 is classed as GHRP; ghrelin receptor agonist; CJC-1295 + Ipamorelin is classed as GHRH analog + selective GHRP blend (GH-secretagogue stack). Reported mechanism: GHRP-6, GHS-R1a agonist with strong orexigenic effect; CJC-1295 + Ipamorelin, Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). Reported half-life: GHRP-6, ~15-30 min; CJC-1295 + Ipamorelin, CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs. Routes in published studies: GHRP-6, SC / Intranasal; CJC-1295 + Ipamorelin, SC injection.
Which has stronger evidence, GHRP-6 or CJC-1295 + Ipamorelin?
GHRP-6 and CJC-1295 + Ipamorelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHRP-6 is graded Anecdotal + Animal Studies, with 7 cited sources on its reference page and 163 indexed studies. CJC-1295 + Ipamorelin is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 5 indexed studies.
Which is more accessible, GHRP-6 or CJC-1295 + Ipamorelin?
Neither GHRP-6 nor CJC-1295 + Ipamorelin is an FDA-approved drug. Catalog status: GHRP-6, Research Chemical; CJC-1295 + Ipamorelin, Compounding Restricted. FDA lists GHRP-6 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are GHRP-6 and CJC-1295 + Ipamorelin ever combined?
GHRP-6 and CJC-1295 + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…